公开(公告)号：US10774036B2

公开(公告)日：2020-09-15

申请号：US16472386

申请日：2017-12-20

Applicant: Novartis AG

Inventor： Florian Karl Kleinbeck-Riniker ,  Tobias Kapferer ,  Hongyong Kim ,  Jie Ku ,  Kurt Laumen ,  Yunzhong Li ,  Wei Peng ,  Thomas Ruch ,  Thierry Schlama ,  Yao Yang

IPC: C07C227/06 ,  C07C229/36 ,  C12P41/00

Abstract: The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a γ-amino-δ-biphenyl-α-methylalkanoic acid, or acid ester, backbone.

公开(公告)号：US20200039935A1

公开(公告)日：2020-02-06

申请号：US16595860

申请日：2019-10-08

Applicant: Novartis AG

Inventor： Mark Clinton Davis ,  Baoqing Gong ,  Denis Har ,  Tobias Kapferer ,  Xuchun Zheng

IPC: C07D211/28 ,  C07D239/42 ,  C07D211/80 ,  C07D211/82

Abstract: The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.

公开(公告)号：US20180057457A1

公开(公告)日：2018-03-01

申请号：US15555103

申请日：2015-03-04

Applicant: Novartis AG

Inventor： Mark Clinton Davis ,  Baoqing Gong ,  Denis Har ,  Tobias Kapferer ,  Xuchun Zheng

IPC: C07D211/28 ,  C07D211/82 ,  C07D239/42

CPC classification number: C07D211/28 ,  C07D211/80 ,  C07D211/82 ,  C07D239/42

Abstract: The present disclosure relates to a method of synthesizing 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine (ceritinib) and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing ceritinib.